<DOC>
	<DOCNO>NCT01882322</DOCNO>
	<brief_summary>The objective study compare efficacy safety group Prograf twice daily therapy convert Advagraf daily therapy group maintain Prograf twice daily therapy .</brief_summary>
	<brief_title>A Study Evaluate Effect Advagraf Conversion From Prograf Liver Transplant Subjects</brief_title>
	<detailed_description>De novo Liver Transplant Recipients divide two group . Both group receive Prograf ( Tacrolimus twice daily therapy ) , Month 1 ( Week 4 ) surgery , Prograf convert Advagraf ( modify release Tacrolimus , daily ) one group , Prograf therapy continue group .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>A subject schedule liver transplantation live donor brain dead In case woman childbearing potential , subject negative pregnancy test prior enrollment consent would practice double contraception throughout study ( Pessary therapy , rhythm method , sexual abstinence , surgical sterilization , menopause otherwise sterile ; however , oral contraceptive exclude . ) A subject terminal hepatic failure liver transplant necessary A subject understand completely aware study objective risk submit write informed consent form study participation A subject receive multiple organ transplant previous organ transplant ( include retransplantation liver ) A subject receive auxiliary transplant use bioartificial liver ( cellular system ) A subject allergic resistant macrolide antibiotic Tacrolimus A subject take Cyclosporine Bosentan ( Tracleer ) may interact Tacrolimus , potassiumsparing diuretic know possibly cause hyperkalemia ( Spironolactone , Triamterene ) screen A subject require immunosuppressive treatment systemic chemotherapy transplant . However , subject receive immunosuppressive treatment le 1 month prior transplant treat underlie hepatic disorder may enrol study treatment discontinue time transplant . A subject malignancy malignant tumor history within past 5 year ; however , subject may enrol study case successfully cure basal cell carcinoma squamous cell carcinoma skin . A subject suffers severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may affect Tacrolimus absorption ( may determine discretion investigator ) A subject type substance abuse , psychological disorder , communication disorder discretion investigator A subject participate another study participate within 28 day study , receive IP nonregistered medication A subject pregnant breastfeed A subject ( transplant recipient ) and/or donor positive HIV A subject comply protocolplanned routine visit schedule A subject appropriate study participation discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FK506</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>immunosuppressant</keyword>
</DOC>